ACT With Chloroquine, Amodiaquine & Sulphadoxine-Pyrimethamine in Pakistan
Chloroquine resistant falciparum malaria in Pakistan is prevalent in every malarious area examined. Resistance to the favoured second-line treatment, sulphadoxine-pyrimethamine S/P is rising fast. To avert a repetition of the resistance catastrophe that occurred in SE Asia it is critical to preserve the effective life of SP by using it in combination with artesunate. Efficacy of ACT with artesunate in combination with chloroquine, SP or amodiaquine for treatment of malaria (falciparum or vivax) will be examined in malaria patients in Pakistan.
Drug: SP, chloroquine, amodiaquine, primaquine, artesunate
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
|Official Title:||Studies on Adding Artesunate to Existing Antimalarial Therapies With Chloroquine, Amodiaquine & Sulphadoxine-Pyrimethamine in Pakistan|
- Day 7 slide clearance rate (complete clearance of trophozoites) assessed by microscopists who are blind to treatment allocation.
- Day 28 slide clearance rate without subsequent recrudescence.
- Day 7 gametocyte prevalence.
- Day 14 gametocyte prevalence
- Fever clearance time
- cure rate (elimination of parasitaemia without recrudescence).
- Rate and time of parasite clearance.
- Rate of resolution of fever.
- Proportion of gametocyte carriers.
- Transmissibility of gametocytes through mosquito feeding studies.
- Molecular characterisation of genetic diversity and resistance before and after treatment.
|Study Start Date:||June 2001|
|Study Completion Date:||December 2004|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00158548
|Principal Investigator:||Kate Graham, MSc||HealthNet International, Peshawar, Pakistan|